In:
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, Computers, Materials and Continua (Tech Science Press), Vol. 29, No. 1 ( 2022-05-04), p. 11-23
Abstract:
We evaluated the association of signal transducer and activator of transcription 3 ( STAT3 ) polymorphisms with the incidence of mammalian target of rapamycin (mTOR) inhibitor-induced interstitial lung disease (ILD) in patients with renal cell carcinoma (RCC). We also used lung-derived
cell lines to investigate the mechanisms of this association. Japanese patients with metastatic RCC who were treated with mTOR inhibitors were genotyped for the STAT3 polymorphism, rs4796793 (1697C/G). We evaluated the association of the STAT3 genotype with the incidence of ILD
and therapeutic outcome. In the 57 patients included in the primary analysis, the ILD rate within 140 days was significantly higher in patients with the GG genotype compared with those with other genotypes (77.8% vs. 23.1%, odds ratio=11.67, 95% confidential interval=3.0644.46). There were no significant differences in progression-free survival or time-to-treatment failure between the patients with the GG genotype and those with other genotypes. An in vitro study demonstrated that some lung-derived cell lines carrying the GG genotype exhibited an increase in the expression of
mesenchymal markers, such as fibronectin, N-cadherin, and vimentin, and decreases in E-cadherin, which is an epithelial marker associated with exposure to everolimus, although STAT3 expression and activity were not related to the genotype. In conclusion, the GG genotype of the STAT3 rs4796793 polymorphism increases the risk of mTOR inhibitor-induced ILD, supporting its use as a predictive marker for RCC.
Type of Medium:
Online Resource
ISSN:
0965-0407
DOI:
10.3727/096504022X16418911579334
Language:
English
Publisher:
Computers, Materials and Continua (Tech Science Press)
Publication Date:
2022
detail.hit.zdb_id:
1114699-0
detail.hit.zdb_id:
2044620-2
Permalink
